Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Inventory (2022 - 2024)

Historic Change in Inventory for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q1 2024 value amounting to $9.3 million.

  • Amylyx Pharmaceuticals' Change in Inventory fell 3044.43% to $9.3 million in Q1 2024 from the same period last year, while for Dec 2024 it was $9.3 million, marking a year-over-year decrease of 8734.7%. This contributed to the annual value of $9.3 million for FY2024, which is 8734.7% down from last year.
  • According to the latest figures from Q1 2024, Amylyx Pharmaceuticals' Change in Inventory is $9.3 million, which was down 3044.43% from $26.5 million recorded in Q4 2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Inventory registered a high of $26.5 million during Q4 2023, and its lowest value of $9.2 million during Q4 2022.
  • In the last 3 years, Amylyx Pharmaceuticals' Change in Inventory had a median value of $13.7 million in 2023 and averaged $15.3 million.
  • Its Change in Inventory has fluctuated over the past 5 years, first soared by 18764.94% in 2023, then crashed by 3044.43% in 2024.
  • Amylyx Pharmaceuticals' Change in Inventory (Quarter) stood at $9.2 million in 2022, then surged by 187.65% to $26.5 million in 2023, then crashed by 65.06% to $9.3 million in 2024.
  • Its Change in Inventory was $9.3 million in Q1 2024, compared to $26.5 million in Q4 2023 and $14.0 million in Q3 2023.